Borte, Michael
Hanitsch, Leif G.
Mahlaoui, Nizar
Fasshauer, Maria
Huscher, Dörte
Speletas, Matthaios
Dimou, Maria
Kamieniak, Marta
Hermann, Corinna
Pittrow, David http://orcid.org/0000-0003-1136-2616
Milito, Cinzia
Funding for this research was provided by:
Takeda Pharmaceuticals International AG
GWT-TUD GmbH, Dresden, Germany
Baxalta Innovations GmbH, a Takeda company
Article History
Received: 15 November 2022
Accepted: 8 March 2023
First Online: 10 April 2023
Declarations
:
: All participants provided their informed consent before participation in the study.
: Not applicable.
: Michael Borte’s institution has received research grant support from CSL Behring, Octapharma, and Baxalta. He has participated in advisory boards for CSL Behring, Octapharma, and Shire.Leif G. Hanitsch received financial support for travelling and congress registration as well as honoraria for presentations and participation in advisory boards from Takeda, Shire, Baxalta, CSL Behring, Octapharma, and LFB.Nizar Mahlaoui received support for CEREDIH research activities and towards participation in scientific advice, training, medical meetings, and international congresses from Grifols, Takeda, LFB Biomédicaments, Octapharma, and CSL Behring.Maria Fasshauer’s institution has received research grant support from CSL Behring, Octapharma, and Baxalta/Shire. She has participated in advisory boards for Baxalta/Shire, has received honoraria for lectures from Shire and CSL-Behring, and has received travel grants from Octapharma until 2018.Dörte Huscher has received travel compensation from Shire.Matthaios Speletas’s institution has received a research grant from Shire.Maria Dimou reports nothing to disclose.Marta Kamieniak is an employee and shareholder of Takeda Development Center Americas, Inc.David Pittrow reports personal fees from Actelion, Amgen, Daiichi Sankyo, Bayer, Aspen, Boehringer Ingelheim, Sanofi-Genzyme, Biogen, Janssen, Viatris, MSD, and Zambon all outside the submitted work. He has acted as a consultant for Baxalta.Cinzia Milito has nothing to disclose.Corinna Hermann was an employee of Baxalta Innovations GmbH, a member of the Takeda group of companies, and a Takeda stock owner.